Bristol Myers announces expanded approvals for Opdivo in U.S., EU,

Bristol Myers (BMY) announced that Opdivo has received approval for two new classical Hodgkin Lymphoma indications in the U.S. and the European Union. The FDA granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. In the EU, the European Commission approved Opdivo in combination with brentuximab vedotin for the treatment of children five years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy.